Head-to-head evidence
insulin glulisine vs LY900014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin glulisine · Apidra
Marketed by Sanofi
NCT00290927 · Phase 3 · completed
The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.
LY900014 · Lyumjev
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · LY900014's landscape